The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis

Wei Zhang, Daphne P. Guh, Paul Grootendorst, Aidan Hollis and Aslam H. Anis

Health Policy, 2024, vol. 144, issue C

Abstract: Background: Canada's Patented Medicine Prices Review Board (PMPRB) uses external and internal reference pricing (IRP) to regulate patented drug list prices. PMPRB has changed external reference countries from 7 to 11 to include countries with prices closer to the OECD median. We examined the impact on the list prices for patented medicines had the amendment been implemented from 2013.

Keywords: External price referencing; Internal price referencing; External reference countries; Patented Medicine Prices Review Board; Patented medicine; Drug list price (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851024000745
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:144:y:2024:i:c:s0168851024000745

DOI: 10.1016/j.healthpol.2024.105064

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().